---
title: "Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Friday When Compared To Competitors"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286617717.md"
description: "Corbus Pharmaceuticals Holdings Inc. (CRBP) shares fell 7.93% to $11.03 on Friday, marking its second consecutive day of losses. The stock is now 46.35% below its 52-week high of $20.56. In comparison, competitors had mixed results, with Vanda Pharmaceuticals down 1.72%, Fortress Biotech up 4.78%, and Viking Therapeutics down 4.54%. Overall, the NASDAQ Composite Index dropped 1.54%."
datetime: "2026-05-15T21:20:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286617717.md)
  - [en](https://longbridge.com/en/news/286617717.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286617717.md)
---

# Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Friday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Corbus Pharmaceuticals Holdings Inc. (CRBP) slid 7.93% to $11.03 Friday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index falling 1.54% to 26,225.14 and Dow Jones Industrial Average falling 1.07% to 49,526.17.

This was the stock's second consecutive day of losses.

Corbus Pharmaceuticals Holdings Inc. closed 46.35% short of its 52-week high of $20.56, which the company reached on October 20th.

The stock underperformed when compared to some of its competitors Friday, as Vanda Pharmaceuticals Inc. (VNDA) fell 1.72% to $6.28, Fortress Biotech Inc. (FBIO) rose 4.78% to $2.41, and Viking Therapeutics Inc. (VKTX) fell 4.54% to $30.27.

Trading volume (166,661) remained 100,153 below its 50-day average volume of 266,814.

Data source: Dow Jones Market Data, FactSet. Data compiled May 15, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

05-15-26 1720ET

### Related Stocks

- [CRBP.US](https://longbridge.com/en/quote/CRBP.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [LABD.US](https://longbridge.com/en/quote/LABD.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [.IXIC.US](https://longbridge.com/en/quote/.IXIC.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)
- [VNDA.US](https://longbridge.com/en/quote/VNDA.US.md)
- [FBIO.US](https://longbridge.com/en/quote/FBIO.US.md)
- [VKTX.US](https://longbridge.com/en/quote/VKTX.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)
- [FBIOP.US](https://longbridge.com/en/quote/FBIOP.US.md)

## Related News & Research

- [Corbus Pharmaceuticals (CRBP) Receives a Buy from LifeSci Capital](https://longbridge.com/en/news/286648720.md)
- [RBC Capital Reaffirms Their Buy Rating on Corbus Pharmaceuticals (CRBP)](https://longbridge.com/en/news/286342985.md)
- [Brokers Offer Predictions for CRBP Q2 Earnings](https://longbridge.com/en/news/286408539.md)
- [Corvus Pharmaceuticals presents Phase 1 soquelitinib data showing durable remissions, favorable safety](https://longbridge.com/en/news/286404245.md)
- [<![CDATA[Pharmaceutical Executive Daily: FDA Approves Baxdrostat]]>](https://longbridge.com/en/news/286807703.md)